<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">KOGURE, YOSHIHITO</style></author><author><style face="normal" font="default" size="100%">SHIGEMATSU, FUMIE</style></author><author><style face="normal" font="default" size="100%">OKI, MASAHIDE</style></author><author><style face="normal" font="default" size="100%">SAKA, HIDEO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring &lt;em&gt;EGFR&lt;/em&gt; Mutations</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1199-1204</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.11364</style></doi><volume><style face="normal" font="default" size="100%">32</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: The aim of this study was to evaluate the relationship between T790M status and the characteristics of non-small cell lung cancer (NSCLC) patients undergoing rebiopsy after initial epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy and whether the site of rebiopsy has an effect on the detection rate for T790M in these patients. Materials and Methods: We retrospectively reviewed the clinical data from stage IV or recurrent NSCLC patients who harbored EGFR mutations and who had initially received EGFR-TKI at our Center from January 2009 to December 2016. Results: Overall, 129 patients were included. The median age at EGFR-TKI therapy initiation was 73 years and 110 showed progressive disease. The presence of T790M mutation was associated with significantly longer progression-free survival (PFS) and EGFR mutation status. The participants' characteristics and rebiopsy site did not affect the T790M detection rate. Conclusion: It is highly recommended that patients with exon 19 deletions and long PFS undergo screening for T790M.</style></abstract></record></records></xml>